Sarcomere disruption in hypertrophic cardiomyopathy (HCM)

Sarcomere disruption in hypertrophic cardiomyopathy (HCM).
ACE = angiotensin-converting enzyme.
[Source]

Hypertrophic cardiomyopathy (HCM) is thought to occur primarily through sarcomere disruption in the face of intact cytoskeleton/sarcolemma.


Secondary disruption
Cascade pathways, such as mitochondrial (energy disruption) abnormalities, sympathetic tone or polymorphisms, signalling pathways, medications and other modifiers, can cause secondary disruption of these primary final common pathways that lead to the phenotype.

Primary disruption
Alternatively, direct mutations in the primary pathways can lead to the phenotype.


Source